Novocure (NVCR) Fundamentals 2026 — Revenue Analysis | SniperIQ
Novocure (NVCR) is a CH-listed Healthcare company in Medical - Devices with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Novocure's market cap?
Novocure (NVCR) has a market capitalization of approximately
What is Novocure's P/E ratio?
Novocure's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 5.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Novocure?
Novocure runs a net profit margin of -25.7%, a gross margin of 75.2%, and an operating margin of -27.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Novocure generate?
Novocure reported revenue of $655M for fiscal year 2025, with net income of -
Does Novocure pay a dividend?
Novocure does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Novocure financially healthy?
Novocure carries a debt-to-equity ratio of 0.71x and a current ratio of 2.90x, with a market beta of 0.94. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Novocure a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Novocure (NVCR) the key facts are: market cap
Track Novocure's full fundamentals live
Get Novocure's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.